SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren

Pharmacogenetics and Genomics

Volumn 23, Issue 1, 2013, Pages 19-24

  Tapaninen, Tuija ^a   Karonen, Tiina ^a   Backman, Janne T ^a   Neuvonen, Pertti J ^a   Niemi, Mikko ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

aliskiren; montelukast; OATP2B1; pharmacogenetics; pharmacokinetics; SLCO2B1

Indexed keywords

ALISKIREN; MONTELUKAST; ORGANIC ANION TRANSPORTER 2; RENIN; SODIUM PHOSPHATE COTRANSPORTER 2B;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84871923576     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835bac90     Document Type: Article

References (17)

1. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics.Br J Pharmacol 2009; 158:693-705.
2. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukastis transporter mediated: a common variant of OATP2B1 is associated withreduced plasma concentrations and poor response. PharmacogenetGenomics 2009; 19:129-138.
3. Mougey EB, Lang JE, Wen X, Lima JJ. Effect of citrus juice and SLCO2B1genotype on the pharmacokinetics of montelukast. J Clin Pharmacol 2011;51:751-760.
4. Laitinen A, Niemi M. Frequencies of single nucleotide polymorphisms ofSLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population. BasicClin Pharmacol Toxicol 2011; 108:9-13.
5. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN,et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren incombination with digoxin, atorvastatin, and ketoconazole in healthy subjects:the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol2008; 48:1323-1338.
6. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinicalpharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet2008; 47:515-531.
7. Tapaninen T, Backman JT, Kurkinen K, Neuvonen PJ, Niemi M. Itraconazole,a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasmaconcentrations and enhances the renin-inhibiting effect of aliskiren. J ClinPharmacol 2011; 51:359-367.
8. Tapaninen T, Neuvonen PJ, Niemi M. Grapefruit juice greatly reduces theplasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren.Clin Pharmacol Ther 2010; 88:339-342.
9. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, et al.Citrus juices inhibit the function of human organic anion- transportingpolypeptide OATP-B. Drug Metab Dispos 2005; 33:518-523. (Pubitemid 40393194)
10. Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT.Gemfibrozil markedly increases the plasma concentrations of montelukast:a previously unrecognized role for CYP2C8 in the metabolism ofmontelukast. Clin Pharmacol Ther 2010; 88:223-230.
11. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Geneticpolymorphisms of human organic anion transporters OATP-C (SLC21A6)and OATP-B (SLC21A9): allele frequencies in the Japanese population andfunctional analysis. J Pharmacol Exp Ther 2002; 302:804-813. (Pubitemid 34787251)
12. Ho RH, Leake BF, Kim RB, Wang Y. OATP2B1 allelic variants differentiallytransport rosuvastatin in vitro [abstract]. Drug Metab Dispos 2006; 38:240-241.
13. Aoki M, Terada T, Ogasawara K, Katsura T, Hatano E, Ikai I, et al. Impact ofregulatory polymorphisms in organic anion transporter genes in thehuman liver. Pharmacogenet Genomics 2009; 19:647-656.
14. Imanaga J, Kotegawa T, Imai H, Tsutsumi K, Yoshizato T, Ohyama T, et al. Theeffects of the SLCO2B1 c.1457C >T polymorphism and apple juice on thepharmacokinetics of fexofenadine and midazolam in humans.Pharmacogenet Genomics 2011; 21:84-93.
15. Ieiri I, Doi Y, Maeda K, Sasaki T, Kimura M, Hirota T, et al. Microdosingclinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), andinteraction (grapefruit juice) profiles of celiprolol following the oralmicrodose and therapeutic dose. J Clin Pharmacol 2012; 52:1078-1089.
16. Chu X, Philip G, Evers R. Comments of Mougey et al. (2009): absorptionof montelukast is transporter mediated: a common variant of OATP2B1is associated with reduced plasma concentrations and poor response.Pharmacogenet Genomics 19:129-138. Pharmacogenet Genomics 2012;22:319-322.
17. Rebello S, Zhao S, Hariry S, Dahlke M, Alexander N, Vapurcuyan A, et al.Intestinal OATP1A2 inhibition as a potential mechanism for the effect ofgrapefruit juice on aliskiren pharmacokinetics in healthy subjects. Eur J ClinPharmacol 2012; 68:697-708.